Immunogenicity Screening

Depending on the therapeutic context, biologics have proven to be surprisingly immunogenic. After years of thorough study of the parameters influencing immunogenicity, EpiVax now uses state-of-the-art immunoinformatics tools and in vitro techniques to predict the potential immunogenicity of proteins, whether these proteins are administered for therapeutic purposes (as in enzymes, monoclonals, replacement proteins) or as vaccines.

Immunogenicity screening and placement of drug candidates on an immunogenicity scale is now used as a means of comparing one protein therapeutic (or Mab) to another, so as to select the best lead to carry forward from preclinical to clinical development, thus reducing the risk of failure due to immunogenicity in the clinical setting.